5-Aminolevulinic acid photodynamic therapy is a safe and effective treatment for female patients with intractable vulvar lichen sclerosus.

Autor: Zheng X; Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China; School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, China., Liu X; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China; Key Laboratory of Gynecologic Oncology of Shandong Province, China., Zhang J; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China; Key Laboratory of Gynecologic Oncology of Shandong Province, China., Liu H; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China., Xu Y; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China., Meng L; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China., Zhang Y; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China., Wang L; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China. Electronic address: wanglili0214@email.sdu.edu.cn., Jia L; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, China. Electronic address: jialin1978@yeah.net.
Jazyk: angličtina
Zdroj: Photodiagnosis and photodynamic therapy [Photodiagnosis Photodyn Ther] 2024 Oct; Vol. 49, pp. 104330. Date of Electronic Publication: 2024 Sep 07.
DOI: 10.1016/j.pdpdt.2024.104330
Abstrakt: Background: Female vulvar lichen sclerosus (VLS) is a chronic inflammatory skin disease of the vulva and its etiology is unknown. The main clinical symptoms are itching, burning and dyspareunia, and there is a lack of effective treatment.
Methods: Clinical and follow-up data of women with VLS who underwent 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) from January 2023 to December 2023 in the department of obstetrics and gynecology, Qilu Hospital of Shandong University, were retrospectively analyzed. According to the inclusion and exclusion criteria, 36 patients with VLS who received ineffective conventional treatment (intractable VLS) were enrolled. Objective signs and subjective symptoms of vulvar lesions were recorded before treatment and 6 months after the end of treatment according to corresponding scoring criteria. Quality of life was evaluated using the Dermatology Life Quality Index (DLQI).
Results: All patients received six sessions of ALA-PDT treatment and follow-up visits. After ALA-PDT treatment, 24 of 36 (66.67 %) patients' itching symptoms completely disappeared, 10 of 36 (27.78 %) patients' itching symptoms were relieved from severe to mild, and only 2 of 36 (5.56 %) patients' symptoms were not significantly relieved. 16 of 36 (44.4 %) patients' itching symptoms completely disappeared, 9 of 36 (25 %) patients' itching symptoms were relieved from severe to mild, and only 2 of 36 (5.56 %) patients still had severe pain. Compared to 22 patients with dyspareunia before treatment, only 9 patients still had dyspareunia with varying degrees of dyspareunia relief after treatment. Clinical signs improved significantly in the patients after ALA-PDT treatment. The total scores of clinical signs were (5.31 ± 1.67 vs 3.67 ± 1.71) before and after treatment. All patients showed improvement in DLQI after treatment. The main side effects of ALA-PDT were pain, erythema and swelling which were transient and tolerable. All patients were "satisfied" or "very satisfied" with the results of the treatment.
Conclusions: ALA-PDT is a safe and effective treatment for women with intractable vulva lichen sclerosus.
Competing Interests: Declaration of competing interest No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: